Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
|Slideshows|August 16, 2018
At the Heart of Depression: 3 New Studies
Author(s)Mark L. Fuerst
New research brings us closer to learning about the associations between psychological states, quality of life, and cardiovascular health.
Advertisement
Advertisement
Related to this article
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
Schizophrenia: A Telltale of the Brain’s Complexity
4
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
5